Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy

Stephanie Gaillard; Jason B. Dinoso; Julia A. Marsh; Amy E. DeZern; Karen A. O'Connell; Adam M. Spivak; Karla Alwood; Christine M. Durand; Richard F. Ambinder; Joel N. Blankson

doi:10.1016/j.jcv.2011.04.002

Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy

Stephanie Gaillard, Jason B. Dinoso, Julia A. Marsh, Amy E. DeZern, Karen A. O'Connell, Adam M. Spivak, Karla Alwood, Christine M. Durand, Richard F. Ambinder, Joel N. Blankson

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

The mechanism of elite control of HIV-1 replication is not fully understood. While immunosuppression due to rituximab based chemotherapy has been associated with increased replication of HBV, CMV, and HIV-1, control of replication-competent HIV-1 was maintained in an elite controller/suppressor treated with a regimen that included vincristine, cyclophosphamide, prednisone, four rounds of plasmapheresis and ten cycles of rituximab. The data suggests that de-novo antibody responses do not play a significant role in the control of viral replication in these patients.

Original language	English (US)
Pages (from-to)	195-198
Number of pages	4
Journal	Journal of Clinical Virology
Volume	51
Issue number	3
DOIs	https://doi.org/10.1016/j.jcv.2011.04.002
State	Published - Jul 2011

Keywords

Elite controllers
Elite suppressors
HIV
Neutralizing antibody
Rituximab

ASJC Scopus subject areas

Virology
Infectious Diseases

Access to Document

10.1016/j.jcv.2011.04.002

Cite this

@article{a5790741fd0f4b5ca453069c1cb1a483,

title = "Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy",

abstract = "The mechanism of elite control of HIV-1 replication is not fully understood. While immunosuppression due to rituximab based chemotherapy has been associated with increased replication of HBV, CMV, and HIV-1, control of replication-competent HIV-1 was maintained in an elite controller/suppressor treated with a regimen that included vincristine, cyclophosphamide, prednisone, four rounds of plasmapheresis and ten cycles of rituximab. The data suggests that de-novo antibody responses do not play a significant role in the control of viral replication in these patients.",

keywords = "Elite controllers, Elite suppressors, HIV, Neutralizing antibody, Rituximab",

author = "Stephanie Gaillard and Dinoso, {Jason B.} and Marsh, {Julia A.} and DeZern, {Amy E.} and O'Connell, {Karen A.} and Spivak, {Adam M.} and Karla Alwood and Durand, {Christine M.} and Ambinder, {Richard F.} and Blankson, {Joel N.}",

year = "2011",

month = jul,

doi = "10.1016/j.jcv.2011.04.002",

language = "English (US)",

volume = "51",

pages = "195--198",

journal = "Journal of Clinical Virology",

issn = "1386-6532",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy

AU - Gaillard, Stephanie

AU - Dinoso, Jason B.

AU - Marsh, Julia A.

AU - DeZern, Amy E.

AU - O'Connell, Karen A.

AU - Spivak, Adam M.

AU - Alwood, Karla

AU - Durand, Christine M.

AU - Ambinder, Richard F.

AU - Blankson, Joel N.

PY - 2011/7

Y1 - 2011/7

N2 - The mechanism of elite control of HIV-1 replication is not fully understood. While immunosuppression due to rituximab based chemotherapy has been associated with increased replication of HBV, CMV, and HIV-1, control of replication-competent HIV-1 was maintained in an elite controller/suppressor treated with a regimen that included vincristine, cyclophosphamide, prednisone, four rounds of plasmapheresis and ten cycles of rituximab. The data suggests that de-novo antibody responses do not play a significant role in the control of viral replication in these patients.

AB - The mechanism of elite control of HIV-1 replication is not fully understood. While immunosuppression due to rituximab based chemotherapy has been associated with increased replication of HBV, CMV, and HIV-1, control of replication-competent HIV-1 was maintained in an elite controller/suppressor treated with a regimen that included vincristine, cyclophosphamide, prednisone, four rounds of plasmapheresis and ten cycles of rituximab. The data suggests that de-novo antibody responses do not play a significant role in the control of viral replication in these patients.

KW - Elite controllers

KW - Elite suppressors

KW - HIV

KW - Neutralizing antibody

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=79959258987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959258987&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2011.04.002

DO - 10.1016/j.jcv.2011.04.002

M3 - Article

C2 - 21550842

AN - SCOPUS:79959258987

SN - 1386-6532

VL - 51

SP - 195

EP - 198

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

IS - 3

ER -

Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this